Moexipril HCl Rx
Generic Name and Formulations:
Moexipril HCl 7.5mg, 15mg; scored tabs.
Various generic manufacturers
Indications for Moexipril HCl:
Take 1 hr before meals. Initially and if not on diuretics: 7.5mg once daily; usual range 7.5–30mg/day in 1–2 divided doses. If on diuretic: suspend diuretic for 2–3 days before starting therapy; resume diuretic if BP not controlled by moexipril alone. If diuretic cannot be discontinued: initially 3.75mg once daily. CrCl ≤40mL/min: initially 3.75mg once daily; max 15mg/day.
History of ACEI-associated or other angioedema. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Hepatic impairment. Renal impairment: monitor for worsening renal function. Hypovolemia. Correct salt/volume depletion before starting therapy. CHF. Renal artery or aortic stenosis. Cerebrovascular or ischemic heart disease. Diabetes. Dialysis (esp. high-flux membrane). Surgery. Monitor WBCs in collagen vascular disease. Discontinue if angioedema, laryngeal edema, jaundice or markedly elevated liver enzymes occurs. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Excessive hypotension with diuretics. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. May increase lithium levels; monitor. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.
Cough, dizziness, diarrhea, flu syndrome, fatigue, pharyngitis, flushing, rash, myalgia; angioedema (eg, intestinal), hyperkalemia, hyponatremia; rare: hepatic failure.
Formerly known under the brand name Univasc.
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D